nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

27.04.2017 | Focussed Research Review

Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy

verfasst von: Hong Jiang, Samarth Hegde, David G. DeNardo

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Tumor-associated fibrosis is characterized by unchecked pro-fibrotic and pro-inflammatory signaling. The components of fibrosis including significant numbers of cancer-associated fibroblasts, dense collagen deposition, and extracellular matrix stiffness, are well appreciated regulators of tumor progression but may also be critical regulators of immune surveillance. While this suggests that the efficacy of immunotherapy may be limited in highly fibrotic cancers like pancreas, it also suggests a therapeutic opportunity to target fibrosis in these tumor types to reawaken anti-tumor immunity. This review discusses the mechanisms by which fibrosis might subvert tumor immunity and how to overcome these mechanisms.

Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214(2):199–210. doi:10.1002/path.2277 CrossRefPubMedPubMedCentral

Wynn TA, Ramalingam TR (2012) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18(7):1028–1040. doi:10.1038/nm.2807 CrossRefPubMedPubMedCentral

Kalluri R (2016) The biology and function of fibroblasts in cancer. Nat Rev Cancer 16(9):582–598. doi:10.1038/nrc.2016.73 CrossRefPubMed

Sugimoto H, Mundel TM, Kieran MW, Kalluri R (2006) Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 5(12):1640–1646CrossRefPubMed

Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6(5):392–401. doi:10.1038/nrc1877 CrossRefPubMed

Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R (2014) Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25(6):719–734. doi:10.1016/j.ccr.2014.04.005 CrossRefPubMedPubMedCentral

Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME, Iacobuzio-Donahue C, Olive KP, Stanger BZ (2014) Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25(6):735–747. doi:10.1016/j.ccr.2014.04.021 CrossRefPubMedPubMedCentral

Erez N, Truitt M, Olson P, Arron ST, Hanahan D (2010) Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 17(2):135–147. doi:10.1016/j.ccr.2009.12.041 CrossRefPubMed

Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimosegawa T, Apte MV, Wilson JS, Ng B, Lau SL, Gunton JE, Wahl GM, Hunter T, Drebin JA, O’Dwyer PJ, Liddle C, Tuveson DA, Downes M, Evans RM (2014) Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159(1):80–93. doi:10.1016/j.cell.2014.08.007 CrossRefPubMedPubMedCentral

10.

Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, Friess H (2012) The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol 9(8):454–467. doi:10.1038/nrgastro.2012.115 CrossRefPubMed

11.

Davies LC, Heldring N, Kadri N, Le Blanc K (2017) Mesenchymal stromal cell secretion of programmed death-1 ligands regulates T cell mediated immunosuppression. Stem Cells 35(3):766–776. doi:10.1002/stem.2509 CrossRefPubMed

12.

de Lourdes Mora-Garcia M, Garcia-Rocha R, Morales-Ramirez O, Montesinos JJ, Weiss-Steider B, Hernandez-Montes J, Avila-Ibarra LR, Don-Lopez CA, Velasco-Velazquez MA, Gutierrez-Serrano V, Monroy-Garcia A (2016) Mesenchymal stromal cells derived from cervical cancer produce high amounts of adenosine to suppress cytotoxic T lymphocyte functions. J Transl Med 14(1):302. doi:10.1186/s12967-016-1057-8 CrossRef

13.

Ino Y, Yamazaki-Itoh R, Oguro S, Shimada K, Kosuge T, Zavada J, Kanai Y, Hiraoka N (2013) Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS One 8(2):e55146. doi:10.1371/journal.pone.0055146 CrossRefPubMedPubMedCentral

14.

Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT (2013) Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA 110(50):20212–20217. doi:10.1073/pnas.1320318110 CrossRefPubMedPubMedCentral

15.

Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT (2010) Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330(6005):827–830. doi:10.1126/science.1195300 CrossRefPubMed

16.

Lo A, Wang LC, Scholler J, Monslow J, Avery D, Newick K, O’Brien S, Evans RA, Bajor DJ, Clendenin C, Durham AC, Buza EL, Vonderheide RH, June CH, Albelda SM, Pure E (2015) Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Res 75(14):2800–2810. doi:10.1158/0008-5472.CAN-14-3041 CrossRefPubMedPubMedCentral

17.

Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA (2009) Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 4(11):e7965. doi:10.1371/journal.pone.0007965 CrossRefPubMedPubMedCentral

18.

Simonian PL, Roark CL, Wehrmann F, Lanham AK, Diaz del Valle F, Born WK, O’Brien RL, Fontenot AP (2009) Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. J Immunol 182(1):657–665CrossRefPubMedPubMedCentral

19.

Palucka AK, Coussens LM (2016) The basis of oncoimmunology. Cell 164(6):1233–1247. doi:10.1016/j.cell.2016.01.049 CrossRefPubMedPubMedCentral

20.

Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G (2010) Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 184(3):1630–1641. doi:10.4049/jimmunol.0902813 CrossRefPubMed

21.

Barnas JL, Simpson-Abelson MR, Brooks SP, Kelleher RJ Jr, Bankert RB (2010) Reciprocal functional modulation of the activation of T lymphocytes and fibroblasts derived from human solid tumors. J Immunol 185(5):2681–2692. doi:10.4049/jimmunol.1000896 CrossRefPubMed

22.

Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM (2003) Conversion of peripheral CD4⁺ CD25- naive T cells to CD4⁺ CD25⁺ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198(12):1875–1886. doi:10.1084/jem.20030152 CrossRefPubMedPubMedCentral

23.

De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP (2011) Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208(3):469–478. doi:10.1084/jem.20101876 CrossRefPubMedPubMedCentral

24.

Epelman S, Lavine KJ, Randolph GJ (2014) Origin and functions of tissue macrophages. Immunity 41(1):21–35. doi:10.1016/j.immuni.2014.06.013 CrossRefPubMedPubMedCentral

25.

Chomarat P, Banchereau J, Davoust J, Palucka AK (2000) IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 1(6):510–514. doi:10.1038/82763 CrossRefPubMed

26.

Wu MH, Hong HC, Hong TM, Chiang WF, Jin YT, Chen YL (2011) Targeting galectin-1 in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis by downregulating MCP-1/CCL2 expression. Clin Cancer Res 17(6):1306–1316. doi:10.1158/1078-0432.CCR-10-1824 CrossRefPubMed

27.

Torres S, Bartolome RA, Mendes M, Barderas R, Fernandez-Acenero MJ, Pelaez-Garcia A, Pena C, Lopez-Lucendo M, Villar-Vazquez R, de Herreros AG, Bonilla F, Casal JI (2013) Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin Cancer Res 19(21):6006–6019. doi:10.1158/1078-0432.CCR-13-1130 CrossRefPubMed

28.

Mathew E, Brannon AL, Del Vecchio A, Garcia PE, Penny MK, Kane KT, Vinta A, Buckanovich RJ, di Magliano MP (2016) Mesenchymal stem cells promote pancreatic tumor growth by inducing alternative polarization of macrophages. Neoplasia 18(3):142–151. doi:10.1016/j.neo.2016.01.005 CrossRefPubMedPubMedCentral

29.

Kim JH, Oh SH, Kim EJ, Park SJ, Hong SP, Cheon JH, Kim TI, Kim WH (2012) The role of myofibroblasts in upregulation of S100A8 and S100A9 and the differentiation of myeloid cells in the colorectal cancer microenvironment. Biochem Biophys Res Commun 423(1):60–66. doi:10.1016/j.bbrc.2012.05.081 CrossRefPubMed

30.

Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS, Fuchs JR, Eubank TD, Frankel WL, Bekaii-Saab T, Bloomston M, Lesinski GB (2013) Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res 73(10):3007–3018. doi:10.1158/0008-5472.CAN-12-4601 CrossRefPubMedPubMedCentral

31.

Khosravi-Maharlooei M, Pakyari M, Jalili RB, Salimi-Elizei S, Lai JC, Poormasjedi-Meibod M, Kilani RT, Dutz J, Ghahary A (2016) Tolerogenic effect of mouse fibroblasts on dendritic cells. Immunology 148(1):22–33. doi:10.1111/imm.12584 CrossRefPubMedPubMedCentral

32.

Cheng JT, Deng YN, Yi HM, Wang GY, Fu BS, Chen WJ, Liu W, Tai Y, Peng YW, Zhang Q (2016) Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation. Oncogenesis 5:e198. doi:10.1038/oncsis.2016.7 CrossRefPubMedPubMedCentral

33.

Stromnes IM, Schmitt TM, Hulbert A, Brockenbrough JS, Nguyen HN, Cuevas C, Dotson AM, Tan X, Hotes JL, Greenberg PD, Hingorani SR (2015) T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell 28(5):638–652. doi:10.1016/j.ccell.2015.09.022 CrossRefPubMedPubMedCentral

34.

Hartmann N, Giese NA, Giese T, Poschke I, Offringa R, Werner J, Ryschich E (2014) Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer. Clin Cancer Res 20(13):3422–3433. doi:10.1158/1078-0432.CCR-13-2972 CrossRefPubMed

35.

Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, Hawkins WG, Shapiro IM, Weaver DT, Pachter JA, Wang-Gillam A, DeNardo DG (2016) Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med 22(8):851–860. doi:10.1038/nm.4123 CrossRefPubMedPubMedCentral

36.

Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, Mami-Chouaib F, Donnadieu E (2012) Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 122(3):899–910. doi:10.1172/JCI45817 CrossRefPubMedPubMedCentral

37.

Wolf K, Te Lindert M, Krause M, Alexander S, Te Riet J, Willis AL, Hoffman RM, Figdor CG, Weiss SJ, Friedl P (2013) Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. J Cell Biol 201(7):1069–1084. doi:10.1083/jcb.201210152 CrossRefPubMedPubMedCentral

38.

O’Connor RS, Hao X, Shen K, Bashour K, Akimova T, Hancock WW, Kam LC, Milone MC (2012) Substrate rigidity regulates human T cell activation and proliferation. J Immunol 189(3):1330–1339. doi:10.4049/jimmunol.1102757 CrossRefPubMedPubMedCentral

39.

He J, Baum LG (2004) Presentation of galectin-1 by extracellular matrix triggers T cell death. J Biol Chem 279(6):4705–4712. doi:10.1074/jbc.M311183200 CrossRefPubMed

40.

Bollyky PL, Wu RP, Falk BA, Lord JD, Long SA, Preisinger A, Teng B, Holt GE, Standifer NE, Braun KR, Xie CF, Samuels PL, Vernon RB, Gebe JA, Wight TN, Nepom GT (2011) ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors. Proc Natl Acad Sci USA 108(19):7938–7943. doi:10.1073/pnas.1017360108 CrossRefPubMedPubMedCentral

41.

McWhorter FY, Davis CT, Liu WF (2015) Physical and mechanical regulation of macrophage phenotype and function. Cell Mol Life Sci 72(7):1303–1316. doi:10.1007/s00018-014-1796-8 CrossRefPubMed

42.

Van Goethem E, Poincloux R, Gauffre F, Maridonneau-Parini I, Le Cabec V (2010) Matrix architecture dictates three-dimensional migration modes of human macrophages: differential involvement of proteases and podosome-like structures. J Immunol 184(2):1049–1061. doi:10.4049/jimmunol.0902223 CrossRefPubMed

43.

Kobayashi N, Miyoshi S, Mikami T, Koyama H, Kitazawa M, Takeoka M, Sano K, Amano J, Isogai Z, Niida S, Oguri K, Okayama M, McDonald JA, Kimata K, Taniguchi S, Itano N (2010) Hyaluronan deficiency in tumor stroma impairs macrophage trafficking and tumor neovascularization. Can Res 70(18):7073–7083. doi:10.1158/0008-5472.CAN-09-4687 CrossRef

44.

Houghton AM, Quintero PA, Perkins DL, Kobayashi DK, Kelley DG, Marconcini LA, Mecham RP, Senior RM, Shapiro SD (2006) Elastin fragments drive disease progression in a murine model of emphysema. J Clin Investig 116(3):753–759. doi:10.1172/JCI25617 CrossRefPubMedPubMedCentral

45.

Weathington NM, van Houwelingen AH, Noerager BD, Jackson PL, Kraneveld AD, Galin FS, Folkerts G, Nijkamp FP, Blalock JE (2006) A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med 12(3):317–323. doi:10.1038/nm1361 CrossRefPubMed

46.

Acerbi I, Cassereau L, Dean I, Shi Q, Au A, Park C, Chen YY, Liphardt J, Hwang ES, Weaver VM (2015) Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol (Camb) 7(10):1120–1134. doi:10.1039/c5ib00040h CrossRef

47.

Nielsen SR, Quaranta V, Linford A, Emeagi P, Rainer C, Santos A, Ireland L, Sakai T, Sakai K, Kim YS, Engle D, Campbell F, Palmer D, Ko JH, Tuveson DA, Hirsch E, Mielgo A, Schmid MC (2016) Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nat Cell Biol 18(5):549–560. doi:10.1038/ncb3340 CrossRefPubMedPubMedCentral

48.

McWhorter FY, Wang T, Nguyen P, Chung T, Liu WF (2013) Modulation of macrophage phenotype by cell shape. Proc Natl Acad Sci USA 110(43):17253–17258. doi:10.1073/pnas.1308887110 CrossRefPubMedPubMedCentral

49.

Springer NL, Fischbach C (2016) Biomaterials approaches to modeling macrophage-extracellular matrix interactions in the tumor microenvironment. Curr Opin Biotechnol 40:16–23. doi:10.1016/j.copbio.2016.02.003 CrossRefPubMed

50.

Perri RT, Kay NE, McCarthy J, Vessella RL, Jacob HS, Furcht LT (1982) Fibronectin enhances in vitro monocyte-macrophage-mediated tumoricidal activity. Blood 60(2):430–435PubMed

51.

Pickup MW, Mouw JK, Weaver VM (2014) The extracellular matrix modulates the hallmarks of cancer. EMBO Rep 15(12):1243–1253. doi:10.15252/embr.201439246 CrossRefPubMedPubMedCentral

52.

Stahl M, Schupp J, Jager B, Schmid M, Zissel G, Muller-Quernheim J, Prasse A (2013) Lung collagens perpetuate pulmonary fibrosis via CD204 and M2 macrophage activation. PLoS One 8(11):e81382. doi:10.1371/journal.pone.0081382 CrossRefPubMedPubMedCentral

53.

Wesley RB 2nd, Meng X, Godin D, Galis ZS (1998) Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscler Thromb Vasc Biol 18(3):432–440CrossRefPubMed

54.

Meyaard L (2008) The inhibitory collagen receptor LAIR-1 (CD305). J Leukoc Biol 83(4):799–803. doi:10.1189/jlb.0907609 CrossRefPubMed

55.

Falanga V, Martin TA, Takagi H, Kirsner RS, Helfman T, Pardes J, Ochoa MS (1993) Low oxygen tension increases mRNA levels of alpha 1 (I) procollagen in human dermal fibroblasts. J Cell Physiol 157(2):408–412. doi:10.1002/jcp.1041570225 CrossRefPubMed

56.

Bentovim L, Amarilio R, Zelzer E (2012) HIF1alpha is a central regulator of collagen hydroxylation and secretion under hypoxia during bone development. Development 139(23):4473–4483. doi:10.1242/dev.083881 CrossRefPubMed

57.

Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber HP, Ferrara N, Johnson RS (2003) HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112(5):645–657CrossRefPubMedPubMedCentral

58.

Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M, Deschoemaeker S, Van Ginderachter JA, Tamagnone L, Mazzone M (2013) Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 24(6):695–709. doi:10.1016/j.ccr.2013.11.007 CrossRefPubMed

59.

Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S (2014) PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211(5):781–790. doi:10.1084/jem.20131916 CrossRefPubMedPubMedCentral

60.

Jiang C, Kim JH, Li F, Qu A, Gavrilova O, Shah YM, Gonzalez FJ (2013) Hypoxia-inducible factor 1alpha regulates a SOCS3-STAT3-adiponectin signal transduction pathway in adipocytes. J Biol Chem 288(6):3844–3857. doi:10.1074/jbc.M112.426338 CrossRefPubMed

61.

Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A (2008) Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 14(19):5947–5952. doi:10.1158/1078-0432.CCR-08-0229 CrossRefPubMed

62.

Zion O, Genin O, Kawada N, Yoshizato K, Roffe S, Nagler A, Iovanna JL, Halevy O, Pines M (2009) Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention. Pancreas 38(4):427–435. doi:10.1097/MPA.0b013e3181967670 CrossRefPubMed

63.

Pines M, Knopov V, Genina O, Lavelin I, Nagler A (1997) Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J Hepatol 27(2):391–398CrossRefPubMed

64.

Juarez P, Mohammad KS, Yin JJ, Fournier PG, McKenna RC, Davis HW, Peng XH, Niewolna M, Javelaud D, Chirgwin JM, Mauviel A, Guise TA (2012) Halofuginone inhibits the establishment and progression of melanoma bone metastases. Cancer Res 72(23):6247–6256. doi:10.1158/0008-5472.CAN-12-1444 CrossRefPubMedPubMedCentral

65.

Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, Le QT, Giaccia AJ (2009) Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15(1):35–44. doi:10.1016/j.ccr.2008.11.012 CrossRefPubMedPubMedCentral

66.

Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM (2009) Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139(5):891–906. doi:10.1016/j.cell.2009.10.027 CrossRefPubMedPubMedCentral

67.

Cox TR, Bird D, Baker AM, Barker HE, Ho MW, Lang G, Erler JT (2013) LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res 73(6):1721–1732. doi:10.1158/0008-5472.CAN-12-2233 CrossRefPubMedPubMedCentral

68.

Gilkes DM, Chaturvedi P, Bajpai S, Wong CC, Wei H, Pitcairn S, Hubbi ME, Wirtz D, Semenza GL (2013) Collagen prolyl hydroxylases are essential for breast cancer metastasis. Cancer Res 73(11):3285–3296. doi:10.1158/0008-5472.CAN-12-3963 CrossRefPubMedPubMedCentral

69.

Miller BW, Morton JP, Pinese M, Saturno G, Jamieson NB, McGhee E, Timpson P, Leach J, McGarry L, Shanks E, Bailey P, Chang D, Oien K, Karim S, Au A, Steele C, Carter CR, McKay C, Anderson K, Evans TR, Marais R, Springer C, Biankin A, Erler JT, Sansom OJ (2015) Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Mol Med 7(8):1063–1076. doi:10.15252/emmm.201404827 CrossRefPubMedPubMedCentral

70.

Chronopoulos A, Robinson B, Sarper M, Cortes E, Auernheimer V, Lachowski D, Attwood S, Garcia R, Ghassemi S, Fabry B, Del Rio Hernandez A (2016) ATRA mechanically reprograms pancreatic stellate cells to suppress matrix remodelling and inhibit cancer cell invasion. Nat Commun 7:12630. doi:10.1038/ncomms12630 CrossRefPubMedPubMedCentral

71.

Sato N, Cheng XB, Kohi S, Koga A, Hirata K (2016) Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma. Acta Pharm Sin B 6(2):101–105. doi:10.1016/j.apsb.2016.01.002 CrossRefPubMedPubMedCentral

72.

Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21(3):418–429. doi:10.1016/j.ccr.2012.01.007 CrossRefPubMedPubMedCentral

73.

Kultti A, Pasonen-Seppanen S, Jauhiainen M, Rilla KJ, Karna R, Pyoria E, Tammi RH, Tammi MI (2009) 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp Cell Res 315(11):1914–1923. doi:10.1016/j.yexcr.2009.03.002 CrossRefPubMed

74.

Hajime M, Shuichi Y, Makoto N, Masanori Y, Ikuko K, Atsushi K, Mutsuo S, Keiichi T (2007) Inhibitory effect of 4-methylesculetin on hyaluronan synthesis slows the development of human pancreatic cancer in vitro and in nude mice. Int J Cancer 120(12):2704–2709. doi:10.1002/ijc.22349 CrossRefPubMed

75.

Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, Antzis M, Cotner CE, Johnson LA, Durham AC, Solomides CC, June CH, Pure E, Albelda SM (2014) Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res 2(2):154–166. doi:10.1158/2326-6066.CIR-13-0027 CrossRefPubMed

76.

Chen M, Xiang R, Wen Y, Xu G, Wang C, Luo S, Yin T, Wei X, Shao B, Liu N, Guo F, Li M, Zhang S, Li M, Ren K, Wang Y, Wei Y (2015) A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts. Sci Rep 5:14421. doi:10.1038/srep14421 CrossRefPubMedPubMedCentral

77.

Wen Y, Wang CT, Ma TT, Li ZY, Zhou LN, Mu B, Leng F, Shi HS, Li YO, Wei YQ (2010) Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci 101(11):2325–2332. doi:10.1111/j.1349-7006.2010.01695.x CrossRefPubMed

78.

Gottschalk S, Yu F, Ji M, Kakarla S, Song XT (2013) A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreading. PLoS One 8(12):e82658. doi:10.1371/journal.pone.0082658 CrossRefPubMedPubMedCentral

79.

Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA (2006) Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 116(7):1955–1962. doi:10.1172/JCI26532 CrossRefPubMedPubMedCentral

80.

Wynn TA, Barron L (2010) Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 30(3):245–257. doi:10.1055/s-0030-1255354 CrossRefPubMedPubMedCentral

81.

Long KB, Gladney WL, Tooker GM, Graham K, Fraietta JA, Beatty GL (2016) IFNgamma and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma. Cancer Discov 6(4):400–413. doi:10.1158/2159-8290.CD-15-1032 CrossRefPubMedPubMedCentral

82.

Zippelius A, Schreiner J, Herzig P, Muller P (2015) Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol Res 3(3):236–244. doi:10.1158/2326-6066.CIR-14-0226 CrossRefPubMed

83.

Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ, Vonderheide RH (2015) Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res 3(4):399–411. doi:10.1158/2326-6066.CIR-14-0215 CrossRefPubMedPubMedCentral

84.

Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Ruckert F, Grutzmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933):1457–1461. doi:10.1126/science.1171362 CrossRefPubMedPubMedCentral

85.

Sulzmaier FJ, Jean C, Schlaepfer DD (2014) FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer 14(9):598–610. doi:10.1038/nrc3792 CrossRefPubMedPubMedCentral

86.

Rustad KC, Wong VW, Gurtner GC (2013) The role of focal adhesion complexes in fibroblast mechanotransduction during scar formation. Differentiation 86(3):87–91. doi:10.1016/j.diff.2013.02.003 CrossRefPubMed

87.

Lagares D, Kapoor M (2013) Targeting focal adhesion kinase in fibrotic diseases. BioDrugs 27(1):15–23. doi:10.1007/s40259-012-0003-4 CrossRefPubMed

88.

Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mouw JK, LeBleu VS, Roy N, Novitskiy SV, Johansen JS, Poli V, Kalluri R, Iacobuzio-Donahue CA, Wood LD, Hebrok M, Hansen K, Moses HL, Weaver VM (2016) Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med 22(5):497–505. doi:10.1038/nm.4082 CrossRefPubMedPubMedCentral

89.

Stokes JB, Adair SJ, Slack-Davis JK, Walters DM, Tilghman RW, Hershey ED, Lowrey B, Thomas KS, Bouton AH, Hwang RF, Stelow EB, Parsons JT, Bauer TW (2011) Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther 10(11):2135–2145. doi:10.1158/1535-7163.MCT-11-0261 CrossRefPubMedPubMedCentral

90.

Serrels A, Lund T, Serrels B, Byron A, McPherson RC, von Kriegsheim A, Gomez-Cuadrado L, Canel M, Muir M, Ring JE, Maniati E, Sims AH, Pachter JA, Brunton VG, Gilbert N, Anderton SM, Nibbs RJ, Frame MC (2015) Nuclear FAK controls chemokine transcription, tregs, and evasion of anti-tumor immunity. Cell 163(1):160–173. doi:10.1016/j.cell.2015.09.001 CrossRefPubMedPubMedCentral

Titel: Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy
verfasst von: Hong Jiang
Samarth Hegde
David G. DeNardo
Publikationsdatum: 27.04.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 8/2017
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-017-2003-1

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy

Abstract

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2017

Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease

Endoplasmic reticulum stress regulates tumor growth and anti-tumor immunity: a promising opportunity for cancer immunotherapy

Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer

Immune biomarkers for chronic inflammation related complications in non-cancerous and cancerous diseases

Phenotype and function of tumor-associated neutrophils and their subsets in early-stage human lung cancer

LILRB receptor-mediated regulation of myeloid cell maturation and function

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Update Onkologie